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Antazoline, as an antihistaminic agent, was
replaced by newer antihistamines, mostly selective
antagonists of the H1 receptor (1). As histamine
may play a role in transplant rejection, antazolineís
antihistaminic properties may be useful in immuno-
suppressive therapy (2). In addition, this drug may
present antiarrhythmic effects (3). Antazoline can
be administered orally, intravenously, intramuscu-
larly or via the ophthalmic route. However, antazo-
line has had sporadic and limited application as an
antiarrhythmic agent (4). Despite the relative lack
of published data, antazoline has been marketed in
Poland and widely used in cardiology wards and
emergency rooms for many years due to its effica-
cy, safety, and rapid onset of action, within minutes
of administration (4, 5). These considerations are
especially relevant to the treatment of patients with
borderline cardiac compensation (3). Most evalua-
tions reporting on the cardiac effect of antazoline
are very old. In the last few years, only six studies
have been published that indicate antazoline could
be of value in the clinical setting and should not be
neglected, as is done at present. There are expecta-
tions with regard to both old and new antiarrhyth-
mic drugs, particularly on the efficacy and safety
profile (6). 
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logical cardioversion among all drugs used in the contemporary treatment of cardiac arrhythmia (up to 85.3%).
The rate of cardioversion with antazoline alone was higher than the combined amiodarone and/or propafenone.
Most of the studies which were reviewed indicated that paroxysmal atrial fibrillation, compared to chronic atri-
al fibrillation, responded more satisfactorily to antazoline treatment. Most patients tolerated antazoline well and
conversion was safe, effective, and smooth. Some research proves that antazoline use may also reduce the rate
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medicine treatment recommendations.
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The aim of this review was to combine both old
and new results from different types of studies (clin-
ical, retrospective, or pharmacokinetic), and attempt
to sum up the positive and negative effects of anta-
zoline in cardiology and emergency medicine, espe-
cially the efficacy of antazoline therapy in various
cardiac arrhythmias that are completely different in
several studies.
Materials and methods
Four databases ñ PubMed, Embase, Google
Scholar, and Web of Science ñ covering reports pub-
lished up to June 2019 were searched with the fol-
lowing keywords and phrases: antazoline, antiar-
rhythmic activity, arrhythmia, ECG, emergency
medicine, and cardiology. The search was limited to
English and Polish papers and to the reference lists
quoted therein. Additionally, other resources such as
Micromedex, Medical Letter, as well as the elec-
tronic Stockley Drugs Interaction were searched.
Checking the reference lists helped identify other
related papers. The selection process was undertak-
en in parallel by two independent researchers work-
ing on each database. The first two authors inde-
pendently studied all clinical reports. Studies with
animals, in vitro studies, and duplicated data were
excluded. 
RESULTS
After all the materials were collected, a critical
review was performed, and the results are presented
in this review. Important information on antazoline
doses, route of administration, and type of arrhyth-
mias are presented (Table 1). 
Mechanism of antazoline action
Antazoline is an H1 receptor antagonist and is,
therefore, able to counteract the symptoms of aller-
gic conjunctivitis mediated by histamine (7).
Antazoline is a first-generation antihistaminic agent
with anticholinergic and quinidine-like properties.
The atropine-like action of antazoline is exemplified
by the facilitation of AñV conduction, and its quini-
dine-like action is evidenced in its ability to prolong
the refractory period of the atrium (8). The mecha-
nism of action is mediated through interference with
membrane permeability to potassium and sodium
(9). Antazoline prolongs the duration of the action
potential and lowers its amplitude, prolongs the
duration of phase 0, reduces the resting potential of
phase 4, and reduces the excitability of cardiac tis-
sue (5). Clinically, antazoline lowers the velocity of
intra-atrial conduction, prolongs the atrial refractory
period, and may improve atrioventricular conduc-
tion allowing fast ventricular response to supraven-
tricular arrhythmias (5). According to the
VaughanñWilliams classification, antazoline
belongs in Class Ia (10).
Pharmacokinetic parameters of antazoline 
Pharmacokinetic studies of antazoline are
scarce (7). The maximal action of antazoline (iv) is
observed after 5 min, and the antiarrhythmic effica-
cy expires after approximately 1 h (40ñ60 min) (11).
In clinical studies of healthy volunteers, the terminal
elimination half-life of antazoline was found to be
2.29 h, with a mean residence time of 3.45 h (12).
Intravenous dosage can be repeated safely at inter-
vals of 2ñ3 h (13).
According to Dreifus et al. (13) the therapeutic
efficacy of oral antazoline appears to last for 4ñ6 h;
therefore, the drug (100ñ200 mg) should be admin-
istered 3ñ4 times daily.
Influence of antazoline on electrocardiographic
and hemodynamic parameters
According to Srzednicki et al. (11), antazoline
does not affect intraventricular conduction or signif-
icantly change the QRS complexes duration; how-
ever, an extended prolongation of the QT interval
was observed from 10 to 45 s beginning from the
2nd minute after administration of the drug and
maintained up to 120 min (end of the observation).
QT prolongation may be an important limitation of
antazoline (3, 14).
Piotrowski et al. (3) examined the effects of
antazoline (administered intravenously in three 100
mg boluses) on hemodynamic and electrocardio-
graphic (ECG) parameters in 10 healthy volunteers.
Antazoline caused significant prolongation of the P
wave, QRS complex, as well as QT interval, and of
the corrected QT interval (QTcF; 101 ± 10 vs. 110 ±
16 ms; 101 ± 12 vs. 107 ± 12 ms; 399 ± 27 vs. 444
± 23 ms; and 403 ± 21 vs. 448 ± 27 ms, respective-
ly). Additionally, there was a significant decrease in
stroke volume (94.9 ± 21.8 vs. 82.4 ± 19.6 mL). A
significant correlation was detected between
changes in plasma antazoline concentration and
changes in cardiac output, heart rate, and diastolic
blood pressure. Antazoline slightly impairs hemody-
namics, thus significantly reducing stroke volume.
The significant prolongation of the P wave and QRS
duration corresponds to a drug-induced prolonga-
tion of conduction, whereas QT prolongation repre-
sents a drug-induced prolongation of repolarization.
Farkowski et al. (15) described that prolongation of
QTc interval by antazoline, can convert atrial fibril-
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lation to sustained atrial tachycardia or flutter
(including 1 : 1 conduction), unmask underlying
conduction disturbances or sick sinus syndrome,
exacerbate existing heart failure, and provoke chest
pain or hypotension. 
BiÒkowski et al. (14) evaluated the electro-
physiological parameters: sinus rhythm cycle length
(SRCL), AH, HV, QRS, QT, QTc intervals,
Wenckebach point (WP), sinus node recovery peri-
od (SNRT), intra- (hRA-CSos) and interatrial con-
duction time (hRA-CSd), right and left atrium
refractory period (RA-; LA-ERP), and atrioventric-
ular node refractory period (AVN-ERP) after suc-
cessful ablation of supraventricular arrhythmias ini-
tially and after 100, 200, and 300 mg of antazoline
which was given intravenously to 15 patients. After
100 mg bolus of antazoline, a significant reduction
in SRCL was observed. Additionally, antazoline
administration caused significant prolongation of
HV, QRS, QTc, hRA-CSos, hRA-CSd intervals,
RA- and LA-ERP. After a total dose of 300 mg of
the drug QT interval prolonged significantly. What
is worth to note, the increase of antazoline dose had
no impact on AH, Wenckebach point, AVN-ERP,
and SNRT.
Side effects of antazoline
Antazoline ñ as a first-generation H1 antihista-
minic ñ may cause adverse effects; mostly because
of poor receptor selectivity. Antazoline may act as
an antimuscarinic, anti-alpha-adrenergic, or even
anti-serotonergic agent (16).
In general, the side effects of antazoline are
seldom serious (e.g., lightheadedness, drowsiness,
dizziness). However, nausea, vomiting, dryness, and
hiccups can be observed, as well as hypotension,
especially when antazoline is rapidly injected. The
drug may exhibit or intensify heart failure by impos-
ing a depressive effect on the myocardium ñ the
inotropic negative effect and increase in the periph-
eral resistance which may result in reduced stroke
volume and the cardiac output (11). This drug may
induce neurologic effects, such as tremors of the fin-
gers and hands, parkinsonian-like states, hallucina-
tion, and grand-mal convulsion (8). Kuch et al. (10)
observed mild side effects (6%), of which the most
significant was hypotension (1%). A very interest-
ing aspect of the side effects, or even toxic effects,
of antazoline therapy was reported in the study of
Reynolds et al. (17), who used higher doses of the
drug in their study than in any others that we
reviewed. Whereas 36% of all of their patients had
transient or minimal side effects, 19.4% of patients
observed severe effects, including chills and fever,
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diarrhea, rashes, and neurologic side effects such as
tremor, depression, lightheadedness, muscle spasm
of legs, and disorientation (17). Leˆn-Sotomayor (8)
described a patient with chronic atrial fibrillation
who became aphasic and developed left-sided hemi-
paresis 24 h after successful conversion induced by
antazoline; however, this patient did not receive
anticoagulants before conversion. This effect can be
attributed much more likely to peripheral embolism-
not drug side effect.
Srzednicki et al. (11) have suggested that in the
light of uncommon side effects (6.9%) by adminis-
tering the dose used in the above study, the drug can
be used for outpatient conditions provided that the
contraindications are ruled out and the blood pres-
sure is being monitored. Increase of a dose within a
range of 250ñ400 mg increased efficiency of thera-
py by 20%, yet it resulted in a fivefold increase of
drug side effects. In addition, the authors have
reported that the correct potassium concentration
may determine the efficacy of antazoline. Leˆn-
Sotomayor (8) suggest that potassium undoubtedly
increases the effectiveness of antazoline therapy;
therefore, the serum levels of this essential element
should be determined and deficits, if any, corrected
before antazoline administration. 
Very high doses of antazoline, approaching
42ñ50 mg/kg, produced a widening of the QRS
complex and decreased myocardial contractility.
Furthermore, Shah et al. (9) found only mini-
mal negative effects during oral antazoline therapy;
nausea and vomiting were more frequent when anta-
zoline was taken on an empty stomach. Addition-
ally, drowsiness was observed, particularly when
antazoline dose was more than 800 mg/day. Despite
the high dose of antazoline used in the study by
Downar et al. (4) there were no serious side effects.
Some patients reported mild gastrointestinal distur-
bances, which may be prevented by taking antazo-
line with food. Additionally, with oral administra-
tion, parkinsonian reactions were detected in only
two cases and were completely reversed after dis-
continuation of antazoline treatment (18).
Most of the reports indicated that the side
effects of antazoline treatment were few and non-
dangerous (19); serious and toxic side effects were
not encountered (20).
DISCUSSION
Studies reviewed were presented in chronological
order.
Kline et al. (20), evaluated the effect of anta-
zoline in 40 patients with premature ventricular sys-
toles, premature atrial systoles, atrial fibrillation,
atrial flutter, ventricular tachycardia, and paroxys-
mal atrial tachycardia. Antazoline was administered
orally (32 patients) in an initial dose of 100 mg
thrice daily for 3 days. The dose was increased to
200 mg, 3 or 4 times daily if an inadequate response
was observed. Eight patients were intravenously
administered antazoline (50ñ800 mg). The drug was
effective in minimizing ectopic beats in patients
with premature atrial and ventricular systoles. The
ectopic concentrations were reduced by 70% or
more in all patients (n = 6) with premature systoles.
More than 70% reduction in the number of ectopic
beats was observed in 19 patients (total number 22)
with ventricular premature systoles. Antazoline
treatment proved unsuccessful when used in patients
with atrial flutter and atrial fibrillation. 
Dreifus et al. (13) indicated that antazoline
administered intravenously (up to 10 mg/kg; 44
patients) and orally (400ñ800 mg; 68 patients)
caused a transient reduction in cardiac output and
stroke volume. Blood pressure was maintained,
whereas peripheral vascular resistance increased.
Antazoline manifests both ñ a direct myocardial
depressant as well as cholinolytic effects; there was
complete suppression of atrial premature systoles in
all subjects. Atrial tachycardia that was observed
only in the group that received intravenous antazo-
line was promptly terminated in 80% of patients.
Antazoline was ineffective (both orally and intra-
venously) in the presence of atrial flutter and fibril-
lation. All patients with frequent ventricular prema-
ture systoles had an adequate response to intra-
venously administered antazoline; however, orally
administered antazoline induced a positive effect in
57 of the 61 patients. Ventricular tachycardia was
terminated in 6 of 10 patients with intravenous anta-
zoline. Therefore, the authors believe antazoline can
be effective in terminating ventricular tachycardia,
multifocal ventricular premature systoles, and non-
paroxysmal nodal tachycardia due to digitalis
excess. However, 1 : 1 conduction resulted in two
cases of paroxysmal atrial tachycardia with block
engendered by digitalis excess. The authors con-
cluded that antazoline is an effective, well-tolerated
antiarrhythmic agent, which may be used in the
treatment of ectopic beats of atrial, nodal, or ven-
tricular origin. In deference to the profound myocar-
dial depressant activity of antazoline, it should be
administered with caution in patients with reduced
cardiac output.
Leˆn-Sotomayor (8) evaluated, in two sched-
ules, the effect of antazoline in 24 patients with
organic heart diseases. In the first model, the dose
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was 100 mg antazoline administered intravenously
and repeated, if required, at intervals of approxi-
mately 5 min, with the total dose not exceeding 100
mg/kg. In the second model, 200 mg antazoline was
given orally immediately after conversion with
intravenous therapy and repeated at 6-hourly inter-
vals with meals. Antazoline appeared to be effective
and safer in arrhythmias associated with intraven-
tricular conduction defects, partially AñV block and
bundle branch block; however, in arrhythmias asso-
ciated with or preceded by a longstanding third-
degree heart block, antazoline is contraindicated.
The authors indicated that antazoline also showed a
high degree of effectiveness against arrhythmias
associated with digoxin intoxication.
Reynolds et al. (17) investigated 115 patients
with different cardiac arrhythmias (premature beats
and paroxysmal arrhythmias) treated with different
doses (oral and intravenous) of antazoline
(100ñ1500 mg), depending on the type of abnormal
rhythm. Antazoline (100ñ200 mg; 4 times a day)
was also used to prevent paroxysmal atrial flutter
(n=6) and paroxysmal atrial fibrillation (n=8), where
it was only slightly effective or completely ineffec-
tive. In the case of paroxysmal ventricular tachycar-
dia (n = 6), 100 mg antazoline administered 4 times
a day was also ineffective; however, when the dose
of the drug was increased to 200 mg 4 times a day,
the number of attacks reduced significantly. The
authors concluded that antazoline seems to be most
effective in the abolition of ventricular tachycardia,
and is beneficial in the prevention of paroxysmal
atrial tachycardia.
Gehring et al. (18) described 20 case studies
where antazoline in different doses was used orally
in the treatment of patients with various arrhythmias
that complicated acute myocardial infarctions and
were refractory to other medicines such as quini-
dine, procainamide, or lidocaine. The authors con-
cluded that atrial fibrillation was successfully con-
verted to normal sinus rhythm with 100 mg antazo-
line thrice daily to 200 mg four times daily. The
authors indicated that this drug has efficacy in atrial
flutter, premature ventricular contractions, and atri-
al tachycardia.
Antani (19) investigated the effect of antazo-
line on different supraventricular and ventricular
cardiac arrhythmia in 50 patients. The drug was
administered intravenously at a rate of 25 mg/min.
The dose was increased by 100 mg until conversion
occurred. The maximum therapeutic dose was 15
mg/kg body weight (bw). This dosage of antazoline
converted paroxysmal atrial tachycardia in 93.75%
of patients, paroxysmal nodal tachycardia in 75%,
ventricular tachycardia in 75%, and atrial fibrillation
in more than 50% of cases. Chronic established atri-
al fibrillation responded less satisfactorily than
paroxysmal fibrillation. One case of atrial flutter
was treated with antazoline to a good outcome.
Additionally, ectopic beats (atrial and ventricular)
were rapidly converted by antazoline.
Shah et al. (9) reported the effect of antazoline
on 65 arrhythmic episodes in 56 patients. In all cases
of ventricular tachycardia, antazoline was adminis-
tered intravenously (50 mg every 5 min until termi-
nation of arrhythmia or a maximum dose of 10
mg/kg bw). In patients with atrial ectopic beats, ven-
tricular ectopic beats, paroxysmal supraventricular
tachycardia (atrial and nodal), or atrial fibrillation,
100 mg antazoline was given orally, every 4 h; how-
ever, if such a schedule was not effective within 24
h, the dose was increased to 200 mg every 4 h for a
further six doses, and, in cases that were not respon-
sive, the dose was further increased to 300 mg every
4 h. The percentage of good response to antazoline
treatment was 83.3% in atrial ectopic beats, 87.5%
in ventricular ectopic beats, 70.0% and 80.0% in
paroxysmal supraventricular tachycardia (atrial or
nodal, respectively), and 60% in ventricular tachy-
cardia. In patients with atrial fibrillation, no signifi-
cant change in the ventricular rate was observed.
Downar et al. (4) investigated seven patients
with severe and debilitating chronic or recurrent
supraventricular tachyarrhythmia. Antazoline was
used because conventional antiarrhythmic therapy
(e.g., quinidine, procainamide, digoxin, propra-
nolol) failed. An initial intravenous administration
of a 5 mg bolus of antazoline was given every 5 min
up to a maximum dose of 400 mg, followed by an
oral maintenance dose of a maximum of 1200
mg/day in divided doses. Antazoline has been rec-
ommended for the treatment of patients with parox-
ysmal or chronic supraventricular tachyarrhythmia
and atrial fibrillation. 
Srzednicki et al. (11) evaluated the effect of
antazoline (5 mg/kg bw to a maximal dose of 400
mg) in a group of 43 patients, most of whom (35
patients) suffered from paroxysmal atrial fibrilla-
tion. The drug was administered iv at a rate of 50
mg/min during the first 2 min, then at 25 mg/min for
between 3 and 6 min, and at 12.5 mg/min between 7
and 22 min. This study demonstrated that the mean
efficient dose of antazoline is 2.8 ± 0.2 mg/kg bw,
whereas the mean time from administration of the
drug to the restoration of the sinus rhythm is 7.3 ±
0.9 min. 
Kuch et al. (10) investigated the effect of intra-
venous antazoline in converting paroxysmal atrial
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fibrillation to sinus rhythm in a large group (n =
1325) of patients with paroxysmal atrial fibrillation
who were treated with antazoline in different doses.
Their study was a retrospective analysis where
patients were divided into four groups based on the
total dose of antazoline required to restore sinus
rhythm. The patients in those four groups received
100, 200, 300, and >300 mg intravenous antazoline,
respectively. According to the antazoline dose, the
authors evaluated the efficacy of antazoline as 46%,
54.5%, 50%, and 20.5% for the lowest and the high-
est dose, respectively. Moreover, the authors evalu-
ated the efficacy of therapy in relation to the selec-
tion of antazoline as the first, second, and third drug
for conversion, and found significant differences in
the effectiveness of the antiarrhythmic procedure ñ
54.5%, 54.7%, and 46.1%, respectively. Addition-
ally, no differences in therapeutic efficacy was
observed in relation to sex (53% for females; 51.4%
for males) and age (<40, 53.7%; 40ñ65, 53.3%; and
>65, 48.6%). The authors inferred that antazoline
therapy was relatively safe within the dose range
from 100 to 300 mg, and they recommended anta-
zoline in paroxysmal AF as the first-line drug when
a ventricular rhythm is <100 beats/min, and as the
second drug when ventricular rhythm increased 100
beats/min after the usage of drug which decreased
heart rate.
Piotrowski et al. (21) examined 290 patients
with Wolff-Parkinson-White syndrome undergoing
ablation; during this procedure, 12 patients devel-
oped sustained atrial fibrillation, which did not stop
for 10 min. In this group of patients, 100 mg anta-
zoline in repeated boluses was used successfully,
and sinus rhythm was restored after a 425 ± 325
seconds. The authors indicated that antazoline dur-
ing atrial fibrillation slightly prolonged RR intervals
as well as reduced the percentage of fully pre-excit-
ed QRS complexes. Antazoline gradually increases
AñA intervals during atrial fibrillation, converting it
into more organized atrial activity (atrial
flutter/tachycardia) before resumption of sinus
rhythm. The authors concluded that antazoline safe-
ly and rapidly coverts atrial fibrillation during abla-
tion of accessory pathways; moreover, antazoline
did not completely block the accessory pathways,
and ablation may be continued.
Balsam et al. (22) evaluated in retrospective,
non-randomized, no placebo-controlled study the
effect of antazoline for termination of atrial fibrilla-
tion in 141 patients (67 with paroxysmal and 74 with
persistent atrial fibrillation) undergoing pulmonary
vein isolation. Antazoline was administered iv (30-
50 mg/min) until sinus rhythm was restored and this
therapy was effective in 56% of patients (in a group
of patients with paroxysmal atrial fibrillation this
ratio reached 90.9%). Less than one-third of persist-
ent atrial fibrillation cases was restored after such
treatment. 
One of the best studies associated with antazo-
line use in cardiac arrhythmias was conducted by
Farkowski et al. (5). It was a randomized, double-
blind, placebo-controlled study of the clinical effi-
cacy of antazoline in rapid cardioversion of parox-
ysmal atrial fibrillation (The AnPAF Study). In
2017 the results of this first randomized controlled
trial with 74 patients with atrial fibrillation episodes
lasting less than 43 h were published (23). 36
patients were treated with antazoline (50 mg diluted
to 10 mL every 5 min up to a total dose of 250 mg ñ
50 mL. The control group (38 patients) received
0.9% saline in boluses of 10 mL every 5 min up to a
maximum volume of 50 mL. During observation
lasted 1.5 h, the successful conversion of paroxys-
mal atrial fibrillation was achieved in 72.2% of
patients received antazoline and in 10.5% cases in
the control group. The median time to restore sinus
rhythm after antazoline administration was 16 min.
Farkowski et al. (24) assessed the comparative
effectiveness and safety of antazoline and
propafenone-based strategies in the pharmacologi-
cal cardioversion of short-duration atrial fibrillation.
In total, 432 cases of cardioversion were analyzed.
Antazoline was administered 334 times, and
propafenone 98 times. Antazoline was administered
at a dose of 50 mg every 3 to 5 min up to a maxi-
mum dose of 250ñ300 mg or until conversion to
sinus rhythm, whereas all patients in the
propafenone group received a fixed dose of 70 mg
propafenone. Cardioversion with antazoline or
propafenone was successful in 71.6% and 55.1% of
patients, respectively. The rate of hospitalization
due to the adverse effects of the treatment was low
and similar in the study groups: 3.0% for antazoline
and 4.1% for propafenone.
Farkowski et al. (25) assessed also the effec-
tiveness and safety of antazoline-based therapy in
patients with a stable coronary artery disease under-
going pharmacological cardioversion of short-dura-
tion AF in the emergency department (retrospective
case-control study, 2008-2012). Antazoline was
administered 334 times (138 patients with stable
coronary artery disease ñ CAD; 196 the control
group). Patients in the CAD group were older and
with a history of myocardial infarction (65 patients).
In CAD group, the antazoline effectiveness was sig-
nificantly higher (82.6% vs 63.8%). Authors indi-
cated that in selected patients even with a history of
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myocardial infarction, antazoline-based cardiover-
sion of short-duration atrial fibrillation can be an
effective and safe choice.
Wybraniec et al. (26) evaluated the success rate
and safety of pharmacological cardioversion of atri-
al fibrillation with intravenous antazoline (CANT
study (Cardioversion With Antazoline Mesylate)).
Antazoline was administered either as a single or
repeated slow (3-minute) undiluted intravenous
bolus of 100 to 200 mg or diluted with a 100-mL
solution of 0.9% NaCl and infused over 5 to 15 min.
180 patients with short-duration atrial fibrillation
received antazoline alone (n = 109) or in combina-
tion with propafenone and/or amiodarone (n = 71),
respectively. Antazoline had the highest success rate
of pharmacological cardioversion among all drugs
(85.3%) and it was comparable with propafenone
and higher than amiodarone treatment. The rate of
cardioversion with antazoline alone was higher than
the combined amiodarone and/or propafenone. 
Farkowski et al. (15) assessed the influence of
antazoline on atrio-venous conduction and other
electrophysiological parameters in patients (n = 14,
mean CHA2DS2-VASc score 1.6) undergoing pul-
monary vein isolation. Antazoline was administered
intravenously in a mean dose of 257.1 mg.
Pulmonary vein potentials and atrial capture during
pulmonary vein stimulation were present before and
after the administration of antazoline. Wenckebach
point and atrial conduction times did not change, but
the atrioventricular node effective refractory period
improved significantly (324.7 ± 84.5 ms vs 284.3 ±
48.6 ms). The drug was effective in all 5 (100%)
cases of AF induction during the electrophysiologi-
cal study and no serious adverse events were
observed. The mean time to conversion was 8.4 ±
6.2 min. Authors indicated that antazoline may be
useful for pharmacological cardioversion of AF
occurring during AF ablation because of the lack of
influence on atrio-venous conduction and high clin-
ical effectiveness. 
Limitation of reviewed studies 
Successful or harmful antiarrhythmic interven-
tion in various types of arrhythmia was observed in
the papers reviewed. It is very difficult to present a
strong recommendation for the treatment of arrhyth-
mia based on the studies in this review. Most of the
studies were not randomized. In particular, the num-
ber of patients in the oldest evaluation was not suf-
ficient to generate strong evidence, and the drug was
administered orally. The most important reason for
the different effects of antazoline therapy observed
between these studies may be the classification of
patients with regard to the therapy. In many studies,
patients with chronic AF were treated with antazo-
line. The second reason could be the route of admin-
istration, which may have a significant effect on the
therapy and, finally, most of the old studies (4, 18)
were conducted with small numbers of patients. The
biggest group of patients were evaluated in Polish
studies: Kuch et al. (10) (n = 1325), Farkowski et al.
(23) (n = 432), and Piotrowski et al. (21) (n = 290).
Multicenter randomized studies are urgently
required in this area, especially for off-label
(according to the Food and Drug Administration
recommendations) treatment of cardiac dysrhyth-
mias (27). Using antazoline in the prevention (oral-
ly administration) of arrhythmias is not recommend-
ed, especially because of the need for frequent dos-
ing and very low availability of the oral antazoline
formulation.
Pharmacological cardioversion of atrial fibrilla-
tion ñ treatment based on 2016 European Society
of Cardiology Guidelines 
Even if electrical cardioversion seems to
restore sinus rhythm quicker and more effectively in
short term (28), the initial treatment of a stable
patient with atrial fibrillation based on pharmaco-
logical cardioversion is more often, especially in
pre-hospital treatment and emergency departments.
Pharmacological cardioversion does not require
sedation or fasting, antiarrhythmic drugs are widely
available in different levels of medical care. In
selected patients with infrequent symptomatic
episodes of paroxysmal atrial fibrillation, drugs (fle-
cainide or propafenone) can be even self-adminis-
trated by themselves at home (ëpill in the pocketí
therapy) (29). Pharmacological cardioversion
restores sinus rhythm in approximately 50% of
patients with recent-onset atrial fibrillation (28). If
the patient is unstable and deteriorating, with any of
the adverse signs and symptoms (syncope, shock,
heart failure, myocardial ischemia), synchronized
electrical cardioversion is immediately required.
In 2016, the European Society of Cardiology
published the guidelines for the management of atri-
al fibrillation which were produced after careful
consideration of the scientific and medical knowl-
edge and the evidence available the time of their
publication. The antazoline is not mentioned in this
document as a possible way of treatment. The
detailed guidelines concerning antiarrhythmic drugs
for the acute restoration of sinus rhythm are present-
ed in Table 2. 
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CONCLUSIONS
After careful consideration of the avail-
able studies concerning the use of antazoline
as an antiarrhythmic drug, we emphasize the
following points:
● Most of the studies indicated that chronic
atrial fibrillation responded less satisfac-
torily to antazoline treatment than paroxy-
smal atrial fibrillation. 
● Most of the patients tolerated antazoline
well, and conversion was safe, effective,
and smooth. 
● In the case of myocardial infarction and
myocarditis ñ because myocardial repo-
larization is decreased, antazoline can
cause hypotension, accelerate atrioven-
tricular conductions, and increase the ven-
tricular response. 
● Antazoline use is contraindicated in
advanced second- and third-degree heart
block, and in severe underlying cardiac
disorders which are defined as heart fail-
ure.
● Antazoline should be administered intra-
venously under continuous cardiac moni-
toring in the setting of emergency depart-
ment, or cardiac intensive care unit.
Antazoline has a definite place in sev-
eral therapeutic interventions for cardiac
arrhythmia. This drug has an effect on elec-
trophysiological parameters of the atrial
muscle and has a rapid onset of action. No
significant negative effect on sinus node
function and atrioventricular conduction in a
unique property among antiarrhythmic
drugs (14). The antazoline should not be
neglected as an old drug, and ought to be
reconsidered in emergency medicine treat-
ment recommendations.
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